Table 3.
All Subjects (n = 30) |
Non-HIV-infected (n = 10) |
HIV-infected (n = 20) |
||||
---|---|---|---|---|---|---|
r | P Value | r | P Value | r | P Value | |
VAT | ||||||
PRA, ng/mL · h | 0.24 | .21 | 0.17 | .64 | 0.66 | .002 |
Ang II, pg/mL | 0.46 | .01 | 0.01 | .98 | 0.58 | .008 |
Serum aldosterone, ng/dL | 0.34 | .07 | 0.12 | .74 | 0.42 | .07 |
Urinary aldosterone excretion, ng per 24 h | 0.30 | .11 | −0.06 | .86 | 0.45 | .04 |
SAT | ||||||
PRA, ng/mL · h | 0.31 | .10 | 0.79 | .007 | 0.16 | .51 |
Ang II, pg/mL | −0.15 | .43 | −0.09 | .80 | −0.17 | .47 |
Serum aldosterone, ng/dL | −0.01 | .96 | −0.18 | .62 | −0.01 | .98 |
Urinary aldosterone excretion, ng per 24 h | −0.003 | .99 | −0.18 | .61 | 0.07 | .76 |
BMI | ||||||
PRA, ng/mL · h | 0.08 | .67 | 0.29 | .42 | −0.004 | .99 |
Ang II, pg/mL | −0.04 | .85 | 0.04 | .92 | −0.06 | .80 |
Serum aldosterone, ng/dL | 0.13 | .50 | −0.22 | .55 | 0.14 | .56 |
Urinary aldosterone excretion, ng per 24 h | 0.21 | .27 | −0.02 | .95 | 0.29 | .21 |
Relationships were assessed by Pearson's correlation coefficient. Determinations were performed under conditions of equivalent low-sodium intake for both groups as described in the text.